SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Stifel upgrades Tandem Diabetes Care to Buy, raises target to $26

Stifel raised its rating from Hold to Buy and its target price from $22 to $26.

TNDM

Related stories